Nielsen, Wolters Kluwer form alliance

In an effort to raise the bar on consumer health targeting, messaging and measurement, Nielsen and Wolters Kluwer Health have launched HealthScape, an information platform.

The platform touts “de-identified patient prescription-related transaction data,” courtesy of Wolters Kluwer Health, combined with “consumer purchasing, attitudinal and behavior information,” from Nielsen, according to a company release. 

Specifically, Nielsen will offer its consumer OTC and consumer packaged goods data from its Homescan and Scantrack services. Wolters Kluwer Health will provide data from its SourceLx and Pharmaceutical Audit Suite (PHAST) services.

Media buyers, for example, can use HealthScape's prescription drug data to assess ad executions with greater precision, according to Rick Crangle, national director at Wolters Kluwer Health. “The same metrics used to calibrate and execute media plans for consumer products can now be employed to bring more accuracy and sophistication to prescription drug media efforts. Key factors for determining [pharmaceutical] ad placement vary by product and market, but include managed care, physician recommendations, race, age and gender,” said Crangle.

Factors driving patient purchasing patterns, which are measurable by HealthScape, include co-morbidities, severity of condition, type of insurance and impact of co-pay versus retail price, managed care formulary controls and mass media advertising, and others, according to Crangle.  

HealthScape products are available in both subscription report format or as ad hoc reports, and can be customized based on a client's needs, noted Crangle. 

“The issue until now has been that manufacturers could not measure the impact of specific marketing or promotional tactics for a given campaign. Now HealthScape links these activities directly to the prescription and OTC-related consumption for individuals,” he said. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.